Why has the Telix Pharmaceuticals share price rocketed 53% in a month?

This biopharmaceutical company has been charging ahead lately.

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Telix shares have exploded more than 50% in a month 
  • In the past 52 weeks, Telix shares have rocketed more than 150% 
  • Telix is developing targeted radiation therapies and diagnostic tools for cancer 

ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) has had a stellar month.

The Telix Pharmaceuticals share price has soared 53% from $7.01 at market close on 3 April to $10.745 at the time of writing. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) has climbed 3% in a month.

Let's take a look at what's been weighing on Telix Pharmaceuticals shares lately.

What's going on?

Telix is developing therapeutic and diagnostic products for cancer and rare diseases using targeted radiation.

Investors appear to have bought up Telix shares in the last month on the back of multiple positive announcements.

On 1 May, Telix shares lifted on positive results from the company's phase three ZIRCON kidney cancer imaging study of TLX250-CDx in clear cell renal cell carcinoma.

New data confirmed the efficacy of TLX250-CDx in masses of 2cm or smaller. Telix chief medical officer Dr Colin Hayward said:

The excellent sensitivity and specificity for small lesions considerably expands the clinical utility and potentially the commercial opportunity for TLX250-CDx.

On 27 April, Telix announced news of a "powerful" artificial intelligence (AI) acquisition. The company unveiled plans to acquire AI-powered clinical decision support software platform Dedicaid.

Commenting on the news, Telix chief scientist Dr Michael Wheatcroft said:

This acquisition provides Telix with a powerful AI development platform that greatly enhances our ability to rapidly generate new applications from clinical imaging data.

Meanwhile, on 17 April, Telix advised it had demonstrated proof of concept using radio labelled Olaratumab to deliver diagnostic and therapeutic radiation to tumours.

Olaratumab is an antibody licensed by Eli Lilly and Company (Lilly). Telix will now progress to human clinical trials.

Also on this day, the company presented a quarter-one FY23 business update. Total revenue rose 27% on the previous quarter to $100.1 million. Compared to the $3.7 million result in the first quarter of 2022, revenue has risen 2605%.

Telix reported a net operating cash inflow of $2.4 million, up $0.8 million on the prior quarter.

Telix Pharmaceuticals share price snapshot

Telix shares have exploded 153% in the last year and nearly 48% year to date.

This ASX 200 healthcare share has a market cap of about $3.41 billion based on the latest share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »